# Semaglutide With Automated Insulin Delivery in Type 1 Diabetes | Buy This GLP

A 72-person trial tested adding semaglutide to automated insulin delivery for adults with type 1 diabetes and obesity. See the results and limits.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/semaglutide-type-1-diabetes-trial
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Semaglutide With Automated Insulin Delivery in Type 1 Diabetes

In a 26-week trial, 36% of adults on semaglutide met a combined glucose and weight target. Every participant already used automated insulin delivery.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Met all three targets at 26 weeks · semaglutide · 36% · placebo · 0% · 72 adults, all using an automated insulin delivery system

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A 26-week trial studied 72 adults with type 1 diabetes and obesity using automated insulin delivery.
-   Thirty-six percent on semaglutide met all three glucose and weight targets. None on placebo did.
-   Everyone continued insulin. The trial did not establish long-term safety.

Seventy-two adults already using automated insulin delivery joined the trial [\[1\]](https://buythisglp.com/research/semaglutide-type-1-diabetes-trial#ref-1). The question of [whether a GLP-1 can replace insulin](https://buythisglp.com/research/can-a-glp1-replace-insulin) is distinct from adding one. Both trial groups continued insulin.

## What the trial measured

Adults with type 1 diabetes and obesity received weekly semaglutide up to 1 mg or placebo for 26 weeks [\[1\]](https://buythisglp.com/research/semaglutide-type-1-diabetes-trial#ref-1). The main outcome required meeting three targets. Glucose had to stay between 70 and 180 mg/dL more than 70% of the time. Time below 70 mg/dL had to be under 4%. Participants also had to lose at least 5% of their weight.

Thirty-six percent of the semaglutide group met all three targets. None in the placebo group did. The difference was 36 percentage points, with a 95% confidence interval of 20.6 to 52.2. Time in range improved by 8.8 percentage points more with semaglutide. The difference in average weight change was 8.8 kg in favor of semaglutide.

## What the safety results can tell us

Each group had two severe low blood sugar events. The researchers reported no diabetic ketoacidosis in either group. An earlier crossover trial reported two episodes of ketosis with normal glucose during semaglutide use [\[2\]](https://buythisglp.com/research/semaglutide-type-1-diabetes-trial#ref-2). Neither episode progressed to ketoacidosis.

Ozempic’s FDA label does not include treatment of type 1 diabetes [\[3\]](https://buythisglp.com/research/semaglutide-type-1-diabetes-trial#ref-3). The [differences between semaglutide brands](https://buythisglp.com/research/is-wegovy-the-same-as-ozempic) matter when checking a product’s approved uses. This trial cannot establish safety over longer periods or in people using insulin injections alone.

## Frequently asked

Can semaglutide replace insulin in type 1 diabetes?

No. All participants continued automated insulin delivery. The trial tested adding semaglutide to insulin.

What was the main outcome?

Thirty-six percent on semaglutide and none on placebo met all three glucose and weight targets by week 26.

Did the trial report ketoacidosis?

It reported no diabetic ketoacidosis. Each group had two severe low blood sugar events.

## Sources

1.  \[1\] Shah VN, et al. (2025). Semaglutide in Adults with Type 1 Diabetes and Obesity NEJM Evidence. [PMID 40550013](https://pubmed.ncbi.nlm.nih.gov/40550013/)
2.  \[2\] Pasqua MR, et al. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes Nature Medicine. [Source](https://www.nature.com/articles/s41591-024-03463-z)
3.  \[3\] Novo Nordisk Inc. (2026). Ozempic injection prescribing information, section 1 DailyMed, U.S. National Library of Medicine. [Source](https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
